Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Antibody test, Biopsy kidney, Blood creatinine, Glomerulonephritis membranous, Renal function test
Clinical narrative: Membranous nephropathy; This literature-non-study case was reported in a literature article and describes the occurrence of GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) in a 56-year-old male patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.   LITERATURE REFERENCE: A case of membranous nephropathy hypothesized to be associated with COVID-19 vaccine.    The patient's past medical history included Hemodialysis (This was stopped a month after discharge as his renal function normalized.). Concurrent medical conditions included Essential hypertension.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) (seriousness criteria hospitalization and medically significant). The patient was treated with PREDNISONE for Adverse event, at an unspecified dose and frequency; RITUXIMAB for Adverse event, at an unspecified dose and frequency and FUROSEMIDE for Adverse event, at an unspecified dose and frequency. At the time of the report, GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test: positive (Positive) Positive and positive Positive for PLA2R in the glomerular deposits suggested primary membranous nephropathy (MN).. On an unknown date, Biopsy kidney: membranous glomerulonephritis Membranous glomerulonephritis with moderate segmental sclerosis, as well as tubulointerstitial fibrosis with neutrophils, consistent with acute interstitial nephritis was showed.. On an unknown date, Blood creatinine: 13 mg/dl 13 mg/dL. On an unknown date, Renal function test: normal (normal) Normal. On an unknown date, Ultrasound kidney: hypocalcemia and hyperphosphatemia was showed Hypocalcemia and hyperphosphatemia were noted, along with medical renal disease on renal ultrasound.. On an unknown date, Urine analysis: eosinophils and nephrotic-range proteinuria Eosinophils and nephrotic-range proteinuria were found..     The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter considered GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) to be related.    No concomitant medications were reported. Patient had dyspnea on exertion and bilateral lower limb swelling and was started on furosemide after two months. Subsequently, his lower limb swelling and exertional dyspnea started worsening. He denied any new medication, dysuria, oliguria, hematuria, fever, or any other symptoms when the kidney biopsy was conclusive for membranous glomerulopathy, patient was started on rituximab. It was stated that Initial evaluation was consistent with kidney failure.  Company Comment: This literature non-study case concerns a 56-year-old male patient with no relevant medical history reported, who experienced the unexpected serious (hospitalization, medically significant) event of Glomerulonephritis membranous, on an unspecified date after receiving the first dose of mRNA-1273 vaccine. Patient had dyspnoea on exertion and bilateral lower limb swelling for two months and was initially started on furosemide. Subsequently when the symptoms were worsening, kidney biopsy was done, and diagnosis of membranous glomerulonephritis was confirmed. The patient was treated with Prednisolone, Rituximab, Furosemide and Haemodialysis on unspecified dates. The outcome was reported as resolving. Antibody test - Positive for PLA2R in the glomerular deposits suggested primary membranous nephropathy. Biopsy kidney: membranous glomerulonephritis Membranous glomerulonephritis with moderate segmental sclerosis, as well as tubulointerstitial fibrosis with neutrophils, consistent with acute interstitial nephritis. Blood creatinine: 13 mg/dl. Renal function test - normal. Ultrasound kidney: hypocalcemia and hyperphosphatemia was showed Hypocalcemia and hyperphosphatemia were noted, along with medical renal disease on renal ultrasound. Urine analysis: eosinophils and nephrotic-range proteinuria Eosinophils and nephrotic-range proteinuria. The outcome was reported as resolving. Details of medical history, concomitant conditions, dates of vaccination and onset of disease were not reported. The non-serious event hypertension could be in turn caused by the renal failure. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This literature non-study case concerns a 56-year-old male patient with no relevant medical history reported, who experienced the unexpected serious (hospitalization, medically significant) event of Glomerulonephritis membranous, on an unspecified date after receiving the first dose of mRNA-1273 vaccine. Patient had dyspnoea on exertion and bilateral lower limb swelling for two months and was initially started on furosemide. Subsequently when the symptoms were worsening, kidney biopsy was done, and diagnosis of membranous glomerulonephritis was confirmed. The patient was treated with Prednisolone, Rituximab, Furosemide and Haemodialysis on unspecified dates. The outcome was reported as resolving. Antibody test - Positive for PLA2R in the glomerular deposits suggested primary membranous nephropathy. Biopsy kidney: membranous glomerulonephritis Membranous glomerulonephritis with moderate segmental sclerosis, as well as tubulointerstitial fibrosis with neutrophils, consistent with acute interstitial nephritis. Blood creatinine: 13 mg/dl. Renal function test - normal. Ultrasound kidney: hypocalcemia and hyperphosphatemia was showed Hypocalcemia and hyperphosphatemia were noted, along with medical renal disease on renal ultrasound. Urine analysis: eosinophils and nephrotic-range proteinuria Eosinophils and nephrotic-range proteinuria. The outcome was reported as resolving. Details of medical history, concomitant conditions, dates of vaccination and onset of disease were not reported. The non-serious event hypertension could be in turn caused by the renal failure. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.